Unprotected left main coronary artery stenting with everolimus (Xience V) drug-eluting stents: A single center retrospective experience

作     者：Juan C. Fernandez-Guerrero Juan A. Herrador Manuel Guzman Victor Aragon Carmen Adamuz 

作者机构：Unidad de Hemodinámica Servicio de Cardiología Complejo Hospitalario de Jaén Jaén Spain 

出 版 物：《World Journal of Cardiovascular Diseases》 (心血管病（英文）)

年 卷 期：2013年第3卷第2期

页      面：183-190页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Percutaneous Coronary Interventions “Off Label” Lesions Prognosis 

摘      要：Objectives: We sought to evaluate the efficacy and safety of unrestricted implantation of everolimus eluting stent Xience V (EES-XV) in a cohort of real- world patients with unprotected left main coronary disease (ULMCD). Background: The second-generation EES-XV stent is currently one of the most commonly used drug-eluting stents in clinical practice. It has been shown to be superior to paclitaxel-eluting stents, but its relative merits on unprotected left main coronary disease have been less extensively assessed. Methods: Between 2007 and 2010, in this single-center registry, we evaluated the clinical outcomes of 98 patients with ULMCD who underwent percutaneous coronary intervention (PCI) with EES-XV. Results: There were no in-hospital deaths. At 25.63 ± 14.41 months of follow-up, 17 patients (17.3%) experienced major adverse coronary event (MACE), death from cardiovascular disease (n = 6;6.1%) and target lesion revascularization (TLR;n = 7;7.1%). The predictors of death from cardiovascular disease were: previous PCI and left ventricular dysfunction. The only predictor of TLR was the placement of 2 stents in the left main coronary artery. Conclusions: In this single- center real-world registry, we found that elective ULMCD stenting with EES-XV provided good short-, medium- and long-term outcomes, with an estimated cumulative need for TLR of 7.1%, a cardiac mortality rate of 6.1%, and a MACE rate of 17.3% at 2 years.